Effect of estrogens on skin aging and the potential role of selective estrogen receptor modulators

Climacteric

Volumn 10, Issue 4, 2007, Pages 289-297

  Verdier Sevrain S ^a  

^a Bio Hybrid   (United States)

Author keywords

Hormone replacement therapy; Phytoestrogens; Selective estrogen receptor modulators; Skin aging; Topical estrogen

Indexed keywords

11 [4 (2 DIMETHYLAMINOETHOXY)PHENYL]ESTRADIOL; 4 (1,2 DIPHENYL 1 BUTENYL)CINNAMIC ACID; 4 [4 METHYL 2 [4 [2 (1 PIPERIDINYL)ETHOXY]PHENYL] 7 PIVALOYLOXY 2H 1 BENZOPYRAN 3 YLPHENYL] PIVALATE; ARZOXIFENE; BAZEDOXIFENE; CENTCHROMAN; CLOMIFENE; CLOMIFENE CITRATE; CONJUGATED ESTROGEN; CYPROTERONE ACETATE; DAIDZEIN; DROLOXIFENE; ESTRADIOL; ESTRADIOL VALERATE; ESTRIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; GENISTEIN; GW 7604; HYALURONIC ACID; IDOXIFENE; ISOFLAVONE; LASOFOXIFENE; MDL 103323; MIPROXIFENE PHOSPHATE; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; NAFOXIDINE; OSPEMIFENE; PHYTOESTROGEN; PIPENDOXIFENE; RALOXIFENE; SCH 57050; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SERAPHENE; TAMOXIFEN; TAMOXIFEN CITRATE; TOREMIFENE; TRIOXIFENE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZK 119010;

AGING; BREAST CANCER; CLINICAL TRIAL; CUTANEOUS PARAMETERS; DEPRESSION; DRUG DOSE COMPARISON; DRY SKIN; ENDOMETRIUM CANCER; FATIGUE; HAIR GROWTH; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; INSOMNIA; LOW DRUG DOSE; MALE TYPE ALOPECIA; MENOPAUSAL SYNDROME; MENOPAUSE; NONHUMAN; OSTEOPOROSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; SKIN BLOOD FLOW; SKIN CONDUCTANCE; SKIN FUNCTION; SKIN PIGMENTATION; SKINFOLD THICKNESS; SWEATING; UNSPECIFIED SIDE EFFECT; UROGENITAL TRACT MALFORMATION; VENOUS THROMBOEMBOLISM; WRINKLE;

ADMINISTRATION, TOPICAL; COLLAGEN; ESTRADIOL CONGENERS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HAIR; HUMANS; MENOPAUSE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SKIN AGING; SKIN PHYSIOLOGY;

EID: 34547188799     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130701467157     Document Type: Review

References (62)

1. Wise PM, Krajnak KM, Kashon ML. Menopause; the aging of multiple pacemakers. Science 1996;273:67-70
2. Gilchrest BA. Age associated changes in the skin. J Am Geriatr Soc 1982;30:139-42
3. Kligman AM, Kligman LH. Fitzpatrick's Dermatology in General Medicine, 5th edn, Vol. 1. New York: McGraw-Hill, 1999:1717-23
4. Schmidt JB, Binder M, Macheiner W, Kainz Ch, Gitsch G, Bieglmayer Ch. Treatment of skin ageing symptoms in perimenopausal females with estrogen compounds. A pilot study. Maturitas 1994;20:25-30
5. Sator PG, Schmidt JB, Rabe T, Zouboulis CC. Skin aging and sex hormones in women. Clinical perspectives for intervention by hormone replacement therapy. Exp Dermatol 2004;13(Suppl 4):36-40
6. Pierard GE, Letawe C, Dowlati A, Pierard-Franchimont C. Effect of hormone replacement therapy for menopause on the mechanical properties of skin. J Am Geriatr Soc 1995;43:662-5
7. Pierard-Franchimont C, Letawe C, Goffin V, Pierard GE. Skin water-holding capacity and transdermal estrogen therapy for menopause: a pilot study. Maturitas 1995;22:151-4
8. Snell RS, Turner R. Skin pigmentation in relation to menstrual cycle. J Invest Dermatol 1966;47:147-55
9. Harvell J, Hussona Saeed I, Maibach HI. Changes in transepidermal water loss and cutaneous blood flow during the menstrual cycle. Contact Dermatatis 1992;275:294-301
10. Hall GK, Phillips TJ. Skin and hormone therapy. Clin Obstet Gynecol 2004;47:437-49
11. Thornton MJ. Oestrogen functions in skin and skin appendages. Expert Opin Ther Targets 2005;9:617-29
12. Albright F, Smith PH, Richardson A. Postmenopausal osteoporosis - its clinical features. JAMA 1941;116:2465-74
13. Brincat M, Kabalan S, Studd JW, Moniz CF, de Trafford J, Montgomery JA. Study of the decrease of skin collagen content, skin thickness, and the bone mass in the postmenopausal women. Obstet Gynecol 1987;70:840-5
14. Affinito P, Palomba S, Sorrentino C, et al. Effects of postmenopausal hypoestrogenism on skin collagen. Maturitas 1999;33:239-47
15. Castelo-Branco C, Duran M, Gonzales-Merlo J. Skin collagen and bone changes related to age and hormone replacement therapy. Maturitas 1992;14:113-19
16. Callens A, Vaillant L, Lecomte P, et al. Does hormonal skin aging exist? A study of the influence of different hormone therapy regimens on the skin of postmenopausal women using non-invasive measurement techniques. Dermatology 1996;193:289-94
17. Maheux R, Naud F, Rioux M, et al. A randomized, double-blind, placebo-controlled study on the effect of conjugated estrogens on skin thickness. Am J Obstet Gynecol 1994;170:642-9
18. Sauerbronn AVD, Fonseca AM, Bagnoli VR, Saldiva PH, Pinotti JA. The effects of systemic hormone replacement therapy on the skin of the postmenopausal women. Int J Gynecol Obstet 2000;68:35-41
19. Varila E, Rantala I, Oikarinen A, et al. The effect of topical oestradiol on skin collagen of postmenopausal women. Br J Obstet Gynaecol 1995;102:985-9
20. Madison KC. Barrier function of the skin: "la raison d'etre" of the epidermis. J Invest Dermatol 2003;121:231-41
21. Holbrook KA, Wolff K. Fitzpatrick's Dermatology in General Medicine, 3rd edn. New York: McGraw-Hill, 1987:93-131
22. Dunn L, Damesyn M, Moore A, Reuben DB, Greendale GA. Does estrogen prevent skin aging? Results from the First National Health and Nutritional Examination Survey. Arch Dermatol 1997;133:339-42
23. Denda M, Koyama J, Hori J, et al. Age- and sex-dependent change in stratum corneum sphingolipids. Arch Dermatol Res 1993;285:415-17
24. Grosman N, Hvidberg E, Schou J. The effect of oestrogenic treatment on the acid mucopolysaccharide pattern in skin of mice. Acta Pharmacol Toxicol 1971;30:458-64
25. Danforth DN, Veis A, Breen M, Weinstein HG, Buckingham JC, Manalo P. The effect of pregnancy and labor on the human cervix: changes in collagen, glycoproteins, and glycoaminoglycans. Am J Obstet Gynecol 1974;120:641-51
26. Bosset S, Barre P, Chalon A, et al. Skin ageing: clinical and histopathologic study of permanent and reducible wrinkles. Eur J Dermatol 2002;12:247-52
27. Creidi P, Faivre B, Agache P, Richard E, Haudiquet V, Sauvanet JP. Effect of a conjugated oestrogen (Premarin) cream on ageing facial skin. A comparative study with a placebo cream. Maturitas 1994;19:211-23
28. Sumino H, Ichikawa S, Abe M, et al. Effects of aging and postmenopausal hypoestrogenism on skin elasticity and bone mineral density in Japanese women. Endocrine J 2004;51:159-64
29. Punnonen R, Vaajalahti P, Teisala K. Local estriol treatment improves the structure of elastic fibers in the skin of postmenopausal women. Ann Chir Gynaecol 1987;202(Suppl):39-41
30. Muller-Rover S, Handjiski B, Van der Veen C, et al. Comprehensive guide to the accurate classification of murine hair follicles in distinct hair cycle stages. J Invest Dermatol 2001;117:3-15
31. Lynfield YL. Effect of pregnancy on the human hair cycle. J Invest Dermatol 1960;35:323-7
32. Whiting DA. Diagnosis of Alopecia. Current Concepts. Kalamazoo: A scope Pub Upjohn Co., 1990
33. Rebora A. Pathogenesis of androgenetic alopecia. Am Acad Dermatol 2004;50:77-9
34. Ekoe JM, Burckhardt P, Ruedi B. Treatment of hirsutism, acne and alopecia with cyproterone acetate. Dermatologica 1980;160:398-404
35. Hoffmann R, Happle R. Finasteride is the main inhibitor of 5 alpha-reductase activity in microdissected dermal papillae of human hair follicles. Arch Dermatol Res 1999;291:100-3
36. Schuhmacher-Stock U. Estrogen treatment of hair diseases. In Orfanos CE, Montagna W, Stüttgen G, eds. Hair Research. Berlin: Springer-Verlag, 1981
37. Orfanos CE, Vogels L. Lokaltherapie der Alopecia androgenetica mit 17alpha-Oestradiol: eine kontrollierte randomisierte Doppelblindstudie. Dermatologica 1980;161:124-32
38. Niiyama R, Happle R, Hoffmann R. Influence of estrogens on the androgen metabolism in different subunits of human hair follicles. Eur J Dermatol 2001;11:165-8
39. Couse JF, Lindzey J, Grandien K, Gustafsson JA, Korach KS. Tissue distribution and quantitative analysis of estrogen receptor-alpha (ER alpha) and estrogen receptor beta (ER beta) messenger ribonucleic acid in the wild-type and ER-alpha-knockout mouse. Endocrinology 1997;138:4616-21
40. Pappas TC, Gametchu B, Yannariello-Brown J, Collins TJ, Watson CS. Membrane estrogen receptors identified by multiple antibody labeling and impeded ligand binding. FASEB 1995;J9:404-41
41. Thornton MJ, Taylor AH, Mulligan K, et al. Oestrogen receptor beta is the predominant oestrogen receptor in human scalp skin. Exp Dermatol 2003;12:181-90
42. Verdier-Sevrain S, Yaar M, Cantatore J, Traish A, Gilchrest BA. Estradiol induces proliferation of keratinocytes via receptor-mediated mechanisms. FASEB J 2004;11:1252-4
43. Rossouw JE, Anderson Gl, Prentice RL, et al. Risk and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33
44. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13
45. Burger H, Archer D, Barlow D, et al. Practical recommendations for hormone replacement therapy in the peri- and postmenopause. Climacteric 2004;7:1-7
46. Speroff L, Kenemans P, Burger HG. Practical guidelines for postmenopausal hormone therapy. Maturitas 2005;51:4-7
47. Gambacciani M, Genazzani AR. Hormone replacement therapy: the benefits in tailoring the regimen and dose. Maturitas 2001;40:195-201
48. Burger H. Hormone replacement therapy in the post-Women's Health Initiative era. Report of a meeting held in Funchal, Madeira, February 24-25. Climacteric 2003;6(Suppl 1):11-36
49. Stevenson J. HRT, osteoporosis and regulatory authorities: Quis custodiet ipsos custodes? Hum Reprod 2006;21:1668-71
50. Sator PG, Schmidt JB, Sator MO, Huber JC, Honigsmann H. The influence of hormone replacement therapy on skin ageing. A pilot study. Maturitas 2001;39:43-5
51. Santen RJ, Pinkerton JV, Conaway M, et al. Treatment of urogenital atrophy with low-dose estradiol: preliminary results. Menopause 2002;9:179-87
52. Hejlova P, Zivny J. Effect of vaginal estriol on urogenital symptoms in postmenopausal women. Ceska Gynekol 2004;69:329-35
53. Kurzer MS, Xu X. Dietary phytoestrogens. Annu Rev Nutr 1997;17:353-81
54. Makela S, Santti R, Salo L, McLachlan JA. Phytoestrogens are partial estrogen agonists in the adult male mouse. Environ Health Perspect 1995;103:123-7
55. Bowers JL, Tyulmenkov VV, Jernigan SC, Klinge CM. Resveratrol acts as a mixed agonist/antagonist for estrogen receptor alpha and beta. Endocrinology 2000;141:3657-67
56. Wei H, Saladi R, Lu Y, et al. Isoflavone genistein: photoprotection and clinical implications in dermatology. J Nutr 2003;133:3811-19S
57. Miyazaki K, Hanamizu T, Iizuka R, Chiba K. Genistein and daidzein stimulate hyaluronic acid production in transformed human keratinocyte culture and hairless mouse skin. Skin Pharmacol Appl Skin Physiol 2002;15:175-83
58. Bayerl C, Keil D. Isoflavonoide in der Behandlung der Hautalterung postmenopausaler Frauen. Akt Dermatol 2002;28:14-18
59. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637-45
60. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA 1999;281:2189-97
61. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-7
62. Surazynski A, Jarzabek K, Haczynski J, Laudanski P, Palka J, Wolczynski S. Differential effects of estradiol and raloxifene on collagen biosynthesis in cultured human skin fibroblasts. Int J Molecular Med 2003;12:803-9